PMID- 33758541
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - Molecular Heterogeneity of Xp11.2 Translocation Renal Cell Carcinoma: The 
      Correlation Between Split Signal Pattern in FISH and Prognosis.
PG  - 2419-2431
LID - 10.2147/CMAR.S297457 [doi]
AB  - PURPOSE: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a distinct 
      subtype of renal cell carcinoma (RCC) characterized by chromosomal translocations 
      involving TFE3 gene. TFE3 break-apart fluorescence in situ hybridization (FISH) 
      assay is an effective tool to diagnose Xp11.2 tRCC. The aim of this study is to 
      evaluate the correlation between split signal pattern in FISH and the 
      clinicopathological characteristics of Xp11.2 tRCC. PATIENTS AND METHODS: We 
      reviewed 2037 RCC patients who underwent partial nephrectomy or radical 
      nephrectomy from January 2007 to March 2020 in our institution. Forty-nine cases 
      were diagnosed as Xp11.2 tRCC and their split signal patterns were evaluated. 
      X-tile software was used to determine the optimal cut-off value of the percentage 
      of split signal in FISH. Kaplan-Meier analysis and Cox regression analysis were 
      performed to assess the relationship between signal pattern of FISH and the 
      prognosis. RESULTS: Among the 49 patients, 13 patients and 36 patients were 
      classified into high and low split signal group, respectively. Nine cases showed 
      extra amplification signal pattern and 40 cases showed typical translocation 
      signal pattern. Multivariate analysis demonstrated that high percentage of split 
      signal and amplification signal pattern were the independent predictors for 
      progression-free survival (PFS) whereas only pT stage was associated 
      independently with overall survival (OS). CONCLUSION: Xp11.2 tRCC cases with high 
      percentage of split signals or amplification signal pattern may have a worse 
      outcome, and the two indicators need to be highlighted in clinical practice.
CI  - (c) 2021 Zhu et al.
FAU - Zhu, Yiqi
AU  - Zhu Y
AUID- ORCID: 0000-0002-3260-2108
AD  - Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
FAU - Pu, Xiaohong
AU  - Pu X
AD  - Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
FAU - Dong, Xiang
AU  - Dong X
AD  - Department of Urology, Drum Tower Clinical Medical School of Nanjing Medical 
      University, Nanjing, Jiangsu, People's Republic of China.
FAU - Ji, Changwei
AU  - Ji C
AD  - Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
FAU - Guo, Hongqian
AU  - Guo H
AD  - Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
FAU - Li, Dongmei
AU  - Li D
AD  - Immunology and Reproduction Biology Laboratory & State Key Laboratory of 
      Analytical Chemistry for Life Science, Medical School, Nanjing University, 
      Nanjing, Jiangsu, People's Republic of China.
AD  - Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing, 
      Jiangsu, People's Republic of China.
FAU - Zhao, Xiaozhi
AU  - Zhao X
AD  - Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
FAU - Gan, Weidong
AU  - Gan W
AD  - Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210315
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7979328
OTO - NOTNLM
OT  - FISH
OT  - TFE3
OT  - Xp11.2 translocation renal cell carcinoma
OT  - amplification
OT  - prognosis
COIS- The authors declare that they have no conflict of interest in this work.
EDAT- 2021/03/25 06:00
MHDA- 2021/03/25 06:01
PMCR- 2021/03/15
CRDT- 2021/03/24 06:44
PHST- 2020/12/15 00:00 [received]
PHST- 2021/02/16 00:00 [accepted]
PHST- 2021/03/24 06:44 [entrez]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/03/25 06:01 [medline]
PHST- 2021/03/15 00:00 [pmc-release]
AID - 297457 [pii]
AID - 10.2147/CMAR.S297457 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Mar 15;13:2419-2431. doi: 10.2147/CMAR.S297457. 
      eCollection 2021.